• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Profound Medical Corp.

    1/23/25 6:38:33 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care
    Get the next $PROF alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 8)


    Profound Medical Corp.

    (Name of Issuer)


    Common Shares

    (Title of Class of Securities)


    74319B502

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    74319B502


    1Names of Reporting Persons

    Gagnon Securities LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,771,667.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,920,060.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,920,060.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.4 %
    12Type of Reporting Person (See Instructions)

    BD, IA


    SCHEDULE 13G

    CUSIP No.
    74319B502


    1Names of Reporting Persons

    Gagnon Advisors, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    896,671.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    896,671.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    896,671.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.0 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    74319B502


    1Names of Reporting Persons

    Neil Gagnon
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    315,195.00
    6Shared Voting Power

    2,868,389.00
    7Sole Dispositive Power

    315,195.00
    8Shared Dispositive Power

    3,031,548.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,346,743.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    11.2 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Profound Medical Corp.
    (b)Address of issuer's principal executive offices:

    2400 Skymark Avenue, Unit 6, Mississauga, Ontario A6, L5R 3G5
    Item 2. 
    (a)Name of person filing:

    Neil Gagnon has sole voting and dispositive power over 315,195 shares of the Issuer's Common Shares (the "Common Shares"). In addition, Mr. Gagnon has shared voting power over 2,868,389 shares of Common Shares and shared dispositive power over 3,031,548 shares of Common Shares. Mr. Gagnon is the managing member and principal owner of Gagnon Securities LLC ("GS"), an investment adviser registered with the U.S. Securities and Exchange Commission ("SEC") under the Investment Advisers Act of 1940, as amended (the "Advisers Act"), and a registered broker-dealer, in its role as investment manager to several customer accounts, foundations, partnerships and trusts (collectively, the "Accounts") to which it furnishes investment advice. GS and Mr. Gagnon may be deemed to share voting power with respect to 1,771,667 shares of Common Shares held in the Accounts and dispositive power with respect to 1,920,060 shares of Common Shares held in the Accounts. GS and Mr. Gagnon expressly disclaim beneficial ownership of all securities held in the Accounts. Mr. Gagnon is also the Chief Executive Officer of Gagnon Advisors, LLC ("Gagnon Advisors"), an investment adviser registered with the SEC under the Advisers Act. Mr. Gagnon and Gagnon Advisors, in its role as investment manager to Gagnon Investment Associates, LLC ("GIA"), a private investment fund, may be deemed to share voting and dispositive power with respect to the 896,671 shares of Common Shares held by GIA. Gagnon Advisors and Mr. Gagnon expressly disclaim beneficial ownership of all securities held by GIA.
    (b)Address or principal business office or, if none, residence:

    1370 Ave. of Americas, 26th Floor, New York, NY 10019
    (c)Citizenship:

    Gagnon Securities LLC Delaware limited liability company Gagnon Advisors, LLC Delaware limited liability company Neil Gagnon USA
    (d)Title of class of securities:

    Common Shares
    (e)CUSIP No.:

    74319B502
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Gagnon Securities LLC 1,920,060 Gagnon Advisors, LLC 896,671 Neil Gagnon 3,346,743
    (b)Percent of class:

    Gagnon Securities LLC 6.4% Gagnon Advisors, LLC 3.0% Neil Gagnon 11.2% Calculation of percentage of beneficial ownership is based on 30,028,476 Common Shares outstanding as of December 10, 2024, based on the Issuer's Prospectus Supplement filed with the Securities and Exchange Commission on December 6, 2024 and Form 6-K filed with the Securities and Exchange Commission on December 10, 2024.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Gagnon Securities LLC 0 Gagnon Advisors, LLC 0 Neil Gagnon 315,195

     (ii) Shared power to vote or to direct the vote:

    Gagnon Securities LLC 1,771,667 Gagnon Advisors, LLC 896,671 Neil Gagnon 2,868,389

     (iii) Sole power to dispose or to direct the disposition of:

    Gagnon Securities LLC 0 Gagnon Advisors, LLC 0 Neil Gagnon 315,195

     (iv) Shared power to dispose or to direct the disposition of:

    Gagnon Securities LLC 1,920,060 Gagnon Advisors, LLC 896,671 Neil Gagnon 3,031,548

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Accounts described above in Item 2 have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, securities held in their respective accounts. To the knowledge of the Reporting Persons, the interest in any such account does not exceed 5% of the class of securities. Except to the extent described herein, the Reporting Persons disclaim beneficial ownership of all such securities.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Gagnon Securities LLC
     
    Signature:/s/ Neil Gagnon
    Name/Title:Neil Gagnon/Managing Member
    Date:01/23/2025
     
    Gagnon Advisors, LLC
     
    Signature:/s/ Neil Gagnon
    Name/Title:Neil Gagnon/Chief Executive Officer
    Date:01/23/2025
     
    Neil Gagnon
     
    Signature:/s/ Neil Gagnon
    Name/Title:Neil Gagnon
    Date:01/23/2025
    Get the next $PROF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PROF

    DatePrice TargetRatingAnalyst
    7/23/2024$16.50Buy
    Lake Street
    7/16/2024$9.00 → $12.00Hold → Buy
    Stifel
    11/28/2023$11.00Hold
    Stifel
    8/4/2023$20.00 → $200.00Strong Buy → Outperform
    Raymond James
    3/21/2023$5.50 → $10.00Buy → Hold
    Jefferies
    3/7/2022$28.00 → $14.00Outperform
    Cowen & Co.
    2/22/2022$28.00 → $23.00Strong Buy → Outperform
    Raymond James
    More analyst ratings

    $PROF
    SEC Filings

    View All

    SEC Form EFFECT filed by Profound Medical Corp.

    EFFECT - Profound Medical Corp. (0001628808) (Filer)

    12/5/25 12:15:31 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Profound Medical Corp. (0001628808) (Filer)

    11/28/25 1:55:55 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    SEC Form S-3 filed by Profound Medical Corp.

    S-3 - Profound Medical Corp. (0001628808) (Filer)

    11/13/25 5:06:18 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Menawat Arun Swarup bought $100,151 worth of shares (22,030 units at $4.55), increasing direct ownership by 4% to 587,089 units (SEC Form 4)

    4 - Profound Medical Corp. (0001628808) (Issuer)

    5/20/25 1:56:42 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Profound Medical with a new price target

    Lake Street initiated coverage of Profound Medical with a rating of Buy and set a new price target of $16.50

    7/23/24 8:51:59 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical upgraded by Stifel with a new price target

    Stifel upgraded Profound Medical from Hold to Buy and set a new price target of $12.00 from $9.00 previously

    7/16/24 7:45:31 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Stifel initiated coverage on Profound Medical with a new price target

    Stifel initiated coverage of Profound Medical with a rating of Hold and set a new price target of $11.00

    11/28/23 7:53:24 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Stanford Medicine's Dr. Pejman Ghanouni Receives RSNA's Cum Laude Award for CAPTAIN Perioperative Data Presentation

    TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that Pejman Ghanouni, MD, PhD, Associate Professor in the Department of Radiology, Division of Body MRI at Stanford University School of Medicine, has received the Cum Laude award for his presentation titled "CAPTAIN Randomized Controlled Trial of MRI-Guided Transurethral Ultrasound Ablation (TULSA) Versus Robotic Radical Prostatectomy" at the 2025 Radiological Society of North America ("RSNA") Annu

    12/4/25 5:00:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings

    TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, announced today the upcoming launch of its TULSA-AI® Volume Reduction module for optimizing the treatment of patients with benign prostatic hyperplasia ("BPH"), or enlarged prostate, at the Radiological Society of North America ("RSNA") meeting taking place in Chicago, Nov. 30-Dec. 4. BPH is a non-cancerous enlargement of the prostate gland due to an overgrowth of prostate cells. It is a common condition as men age, ofte

    11/28/25 7:45:00 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical Celebrates The Hong Center's 200th Independent TULSA Procedure for Prostate Disease

    TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, announced today that The Hong Center Scottsdale, led by Dr. Y. Mark Hong of Integrative Urology in Phoenix, Arizona, has achieved a world-first milestone: 200 TULSA Procedures™ performed independently by a urologist, without radiologist involvement. This landmark establishes a new model for delivering MRI-guided prostate therapy. "Dr. Hong's longstanding commitment to innovation and compassion for his patients made him a

    11/18/25 4:15:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Menawat Arun Swarup bought $100,151 worth of shares (22,030 units at $4.55), increasing direct ownership by 4% to 587,089 units (SEC Form 4)

    4 - Profound Medical Corp. (0001628808) (Issuer)

    5/20/25 1:56:42 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    Financials

    Live finance-specific insights

    View All

    Profound Medical Reports Strong Third Quarter 2025 Financial Results

    TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the third quarter ended September 30, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP).   Business Highlights Revenue grew 87% year-over-year to a record $5.3 million in the third quarter of 2025.Gross margin increased 1,119 basis p

    11/13/25 4:05:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter

    TORONTO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today announced preliminary unaudited revenues for the third quarter of 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars. For the quarter ended September 30, 2025, Profound anticipates total revenues to be in the approximate range of $5.2 million to $5.3 million, representing revenue growth of between 84% and 87% over $2.8 million in the same three-month period a year ag

    10/7/25 7:45:00 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical Announces Second Quarter 2025 Financial Results

    TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the second quarter ended June 30, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP). Business Highlights Utilization of current TULSA-PRO® systems continues to grow, with "same store" procedure volumes up 10% sequentially from Q1-2

    8/14/25 4:05:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Profound Medical Corp.

    SC 13G/A - Profound Medical Corp. (0001628808) (Subject)

    11/14/24 4:27:34 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Profound Medical Corp.

    SC 13G/A - Profound Medical Corp. (0001628808) (Subject)

    8/5/24 7:50:30 AM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Profound Medical Corp. (Amendment)

    SC 13G/A - Profound Medical Corp. (0001628808) (Subject)

    3/13/24 4:00:16 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    $PROF
    Leadership Updates

    Live Leadership Updates

    View All

    Profound Medical Annual General and Special Meeting of Shareholders Voting Results

    TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders that was held today (the "Meeting"). A total of 20,587,011 common shares, representing 68.5% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 4, 2025 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders

    5/14/25 4:45:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer

    – Mr. Tamberrino and Profound's CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes as Profound continues to make final preparations for the permanent CPT® Category 1 codes for TULSA going into effect at the beginning of 2025 – TORONTO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the appointment of Tom Tamberrino as its new Chief Commercial Officer. Abbey Goodman, the Company's current CCO, will t

    10/16/24 4:15:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Profound Medical Annual General Meeting of Shareholders Voting Results

    TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General Meeting of Shareholders that was held today (the "Meeting"). A total of 15,336,388 common shares, representing 62.78% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 5, 2024 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders of the Comp

    5/15/24 5:00:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care